Cure8 research brief
Patients and clinicians want to know whether tofacitinib raises blood clotting or platelet activation risk in ulcerative colitis, because similar safety concerns were reported in other diseases.
Patients with ulcerative colitis considering or taking tofacitinib, prescribing gastroenterologists, and researchers studying drug safety and immune pathways.
The study compared 10 UC patients starting tofacitinib, 10 UC patients on anti-TNF therapy, and 10 healthy controls, with assessments at baseline and after 14 weeks. Platelet aggregation (lumiaggregometry), platelet activation markers (PAC-1, CD62P, CD63 by flow cytometry), and clotting dynamics (ROTEM EXTEM/INTEM) were measured.
The authors report no increase in platelet aggregation or activation with tofacitinib versus anti-TNF or healthy controls. ROTEM showed a longer clot formation time in the INTEM assay for the tofacitinib versus anti-TNF group, but neither patient group differed from healthy controls.
Small sample size (10 per group) and short follow-up (14 weeks) limit detection of rare events. Results are specific to UC patients studied and measured platelet/coagulation lab assays, not population-level thromboembolic outcomes.
Review the original publication for the complete reporting, methods, and context.
Funding disclosed by the source: Instituto de Salud Carlos III; Pfizer; Spanish National Plan for Scientific and Technical Research and Innovation; European Regional Development Fund; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Patients and clinicians considering sequencing of advanced UC therapies may care because this study reports differences in how long patients stayed on second-line treatment depending on the order of anti-TNF agents and...
For people with multi-refractory Crohn’s disease or ulcerative colitis, adding a JAK inhibitor to an existing biologic (advanced combination therapy) may convert partial responses into deeper remission in selected cases,...
Older adults with ulcerative colitis can rarely develop large-vessel giant cell arteritis as an extraintestinal complication.
